N-(5-tert-butylisoxazol-3-yl)-N'-(4-{7-[3-(4-methylpiperazin-1-yl)propoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl}phenyl)urea hydrochloride | 1349576-39-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-(5-tert-butylisoxazol-3-yl)-N'-(4-{7-[3-(4-methylpiperazin-1-yl)propoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl}phenyl)urea hydrochloride
• CAS: 1349576-39-1
• 化学式: C₃₁H₃₇N₇O₃S*ClH
• 分子量: 624.207
• InChiKey: JJNRDQUJEWIHCA-UHFFFAOYSA-N

反应信息

• 作为产物：
  描述：

  N-(5-tert-butylisoxazol-3-yl)-N'-(4-{7-[3-(4-methylpiperazin-1-yl)propoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl}phenyl)urea 在 盐酸 作用下， 以 甲醇 、 甲醚 、 二氯甲烷 为溶剂， 生成 N-(5-tert-butylisoxazol-3-yl)-N'-(4-{7-[3-(4-methylpiperazin-1-yl)propoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl}phenyl)urea hydrochloride
  参考文献：
  名称：

  Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor

  摘要：

  Treatment of AM L patients with small molecule inhibitors of FLT3 kinase has been explored as a viable therapy. However, these agents arc found to be less than optimal for the treatment of AM L because of lack of sufficient potency or suboptimal oral pharmacokinetics (PK) or lack of adequate tolerability at efficacious doses. We have developed a series of extremely potent and highly selective FLT3 inhibitors with good oral PK properties. The first series Of Compounds represented by 1 (A13530) was found to be a potent and selective FLT3 kinase inhibitor with good PK properties. The aqueous solubility and oral PK properties at higher doses in rodents were found to be less than optimal for clinical development. A novel series of compounds were designed lacking the carboxamide group of 1 with an added water solubilizing group. Compound 7 (AC220) was identified front this series to be the most potent and selective FLT3 inhibitor with good pharmaceutical properties, excellent PK profile, and superior efficacy and tolerability in tumor xenograft models. Compound 7 has demonstrated a desirable safety and PK profile in humans and is currently in phase II clinical trials.

  DOI：

  10.1021/jm9007533